Tag:

Prevnar-13

Latest Headlines

Latest Headlines

Pfizer points to pandemic potential of Prevnar 13

In pandemic flu preparation, a lot of focus is placed on protecting against the specific viral strain. Yet analysis of the 1918 pandemic shows secondary bacterial pneumonia directly caused many of the deaths. This brings Pfizer's Prevnar 13 into play, and the Big Pharma is talking up its role.

FDA expands use of Pfizer's Prevnar 13

The FDA will now allow use of Prevnar 13 in children and adolescents ages 6 to 17, a recent expansion that could allow Pfizer to hit lofty sales goals.

Pfizer wins Prevenar 13 expansion in EU

Pfizer has always harbored substantial goals for its pneumococcal conjugate vaccine, and the pharma giant got a leg up Tuesday when the European Commission approved the use of Prevenar 13 in older children and adolescents.

Pfizer's Prevnar 13 posts positive late-stage data

The study of the shot, known as Prevnar in the U.S. and Prevenar in other countries and used to prevent infection by streptococcus pneumonia, showed the immune response to the vaccine in the 18- to 49-year-old age group was noninferior when compared to the response in the 60- to 64-year-old age group.

WHO injects Prevnar 13 with adult prequalification status

Prevnar 13 is the first and only pneumococcal vaccine to be granted WHO prequalification for adults.

CDC delay could temper adult uptake of Pfizer's Prevnar shot

Pfizer ($PFE) has pinned big hopes on Prevnar 13, the latest version of its vaccine against pneumococcus bacteria.

FDA approves Pfizer's Prevnar 13 for adults over 50

Pfizer ($PFE) has won a much-anticipated FDA approval for Prevnar 13 for older adults to prevent pneumonia and other diseases caused by 13 Streptococcus pneumoniae serotypes contained in the vaccine....

FDA experts back Pfizer's Prevnar 13 for older adults

In a 14-1 vote, a panel of FDA experts say Pfizer's ($PFE) Prevnar 13 protected adults over 50 from pneumococcal infections, paving the way for a likely approval in January. Earlier this week agency

FDA delays decision on Pfizer's Prevnar 13

The FDA will take 90 more days to review Pfizer's request that Prevnar 13 be approved for adults 50 and over. Pfizer has submitted additional data gathered from two studies of the vaccine used in

FDA extends Prevnar review on additional data

The FDA has put off its decision on expanding the use of Pfizer's Prevnar 13 vaccine to adults 50 and older. A decision is now expected 90 days later in January 2012. Pfizer release | Report